Pentixapharm Holding AG (FRA:PTP)

Germany flag Germany · Delayed Price · Currency is EUR
1.838
+0.006 (0.33%)
Last updated: Sep 30, 2025, 9:02 AM CET
0.33%
Market Cap45.40M
Revenue (ttm)-1.13M
Net Income (ttm)-20.11M
Shares Outn/a
EPS (ttm)-0.81
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume790
Open1.838
Previous Close1.832
Day's Range1.838 - 1.838
52-Week Range1.432 - 5.100
Betan/a
RSI52.93
Earnings DateNov 14, 2025

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2019
Employees 75
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol PTP
Full Company Profile

Financial Performance

In 2024, Pentixapharm Holding AG's revenue was 1.40 million, a decrease of -78.47% compared to the previous year's 6.51 million. Losses were -13.98 million, 82.9% more than in 2023.

Financial Statements

News

There is no news available yet.